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Prostate cancer (PCa) is the most commonly diagnosed cancer in men, with an estimated 238,000 new cases in the United States this year. It is the second highest cause of 
cancer-related death; nearly 30,000 men in the U.S. die from PCa each year. The discovery of prostate-specific antigen (PSA) as a biomarker for PCa has made it possible to 
detect the disease in early stages. It is estimated that there is often a lag-time of 15 years or more from initially detectable PSA elevation to clinically manifested PCa. In recent 
years, there has been considerable debate about the benefits versus risks of PSA screening, as there is a potential to over-treat indolent disease that may never have caused 
symptoms during a patient’s lifetime. However, novel tumor markers and new mechanistic insights into disease progression may improve prognostic abilities.
Clinical Progression of Prostate Cancer and Histopathology
Most patients are diagnosed after presenting with elevated PSA or abnormal digital rectal exam, followed by a biopsy. Definitive treatments for clinically localized disease are 
surgery and radiation, but patients with low-risk disease or a shorter life expectancy can be managed with active surveillance, which consists of PSA assays and repeat biopsies 
at regular intervals until there is evidence of disease progression. Patients who progress may develop locally advanced or metastatic disease, which is initially treated primarily 
with androgen-deprivation therapy (ADT). However, almost all advanced prostate cancer progresses to castration-resistant disease after a period of ADT.
Histologic grading is based on the Gleason system, which ranges from grade 1 (most differentiated) to 5 (least differentiated). Each specimen is assigned a Gleason score 
based on their most prevalent and second-most prevalent histologic grades. The combination of the two grades gives the total score (ranging from 2 to 10, with most cancers 
falling between 6 and 8). When malignant cells are confined to the prostate acini and the basal cell layer remains at least partially intact, it is defined as prostatic intraepithelial 
neoplasia (PIN). High-grade PIN is an established precursor to adenocarcinoma, which is distinguished by an absence of the basal epithelial layer.
Cell Types of Origin, Genetic Alterations, and Molecular Subtypes
Prostate adenocarcinoma can derive from luminal or basal epithelial cells of the prostatic acini. While malignancies may arise from a single mutation followed by clonal propa-
gation, many prostate cancers contain multiple foci with varying genetic alterations. Tumor heterogeneity at the molecular, cellular, and architectural levels makes it difficult to 
distinguish between synchronous tumors developing from independent oncogenic events versus clonally derived tumors whose cells become highly divergent.
Unlike most cancers that are commonly associated with specific point mutations, PCa involves large-scale genomic rearrangements and extensive copy number altera-
tions involving multiple chromosomes. This phenomenon of chromoplexy often leads to loss of one or both copies of critical tumor suppressor genes such as PTEN, NKX3.1, 
TP53, and CDKN1B as well as oncogenic fusions such as TMPRSS2-ERG, which is observed in ~50% of prostate tumors. Exome and whole-genome sequencing studies have 
provided evidence for distinct molecular subtypes of PCa categorized by specific alterations such as CHD1 deletions, ERG rearrangements, and SPOP mutations.
Chemoprevention
Because of the high prevalence and prolonged latency period of prostate cancer, chemoprevention approaches have been of particular interest. The most promising agents are 
the 5-alpha reductase inhibitors finasteride and dutasteride, which inhibit the conversion of testosterone to dihydrotestosterone, the most active prostatic androgen. Although 
data suggest that finasteride and dutasteride may reduce PCa risk overall, concerns of a potential increased risk of high-grade cancer have hindered their use in chemoprevention.
Mechanisms of Castration Resistance and Advances in Treatment of Castration-Resistant Prostate Cancer
Virtually every patient treated with ADT will eventually develop resistance with subsequent rise in PSA or clinical progression. Although the pathways that lead to castration 
resistance are not fully understood, potential mechanisms include (1) intratumoral androgen biosynthesis, (2) androgen receptor (AR) pathway hypersensitivity via AR gene 
amplification, (3) AR activation by noncognate ligands such as corticosteroids (often mediated by AR mutations), (4) growth factor-mediated increase in AR transcription activity, 
(5) expression of variant AR isoforms that are ligand independent, (6) activation of alternative survival pathways that bypass the AR pathway, and (7) selection of pre-existing 
castration-resistant epithelial stem cells. Castration resistance may involve several of these processes simultaneously as well as undiscovered mechanisms.
The available treatments for castration-resistant prostate cancer (CRPC) have traditionally been limited to cytotoxic chemotherapeutics and palliative measures. However, 
recent novel therapies with proven survival benefits have broadened the armamentarium for this disease state. In particular, Abiraterone is an oral agent that blocks androgen 
production in tumors as well as testis and adrenal gland through irreversible inhibition of products of the CYP17A1 gene. Abiraterone prolongs overall survival in men with 
CRPC previously treated with docetaxel as well as in chemotherapy naive patients. Enzalutamide, another oral agent, blocks AR function by inhibition of androgen binding to 
AR, nuclear translocation of AR, and AR association with nuclear DNA, and also prolongs survival in men with metastatic CRPC after docetaxel treatment.
Activation of the PI3K-AKT-mTOR pathway is likely to play a key role in castration resistance, particularly through its complex regulation involving cross-talk with the AR and 
MAPK pathways. Agents that block various steps in the PI3K-AKT-mTOR pathway are currently being investigated as novel therapeutics for advanced PCa. Such agents may 
be used in the context of combinatorial treatments with agents that target the AR and/or MAPK pathways to counteract positive feedback loops that are activated when only a 
single pathway is targeted.
Mouse Models of Prostate Cancer
Genetically engineered autochthonous mouse models of prostate cancer have played important roles in the elucidation of molecular mechanisms for cancer initiation and pro-
gression. Newer models that display castration-resistant phenotypes are now being used for analyses of drug response and resistance mechanisms.
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